Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects with Solid Tumors
dabrafenib
BRF112680
NCT00880321
Cancer
Phase 1
 
September 2013

Powered by ideaPoint, Inc.